Figure 1.The detailed work process of this study. SETBP1 mutations were determined as a potential biomarker for melanoma and NSCLC clinical ICI treatments.
Figure 1 — SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC | Aging
